EVGN

Evogene Ltd. (EVGN) | Rumor.io

Evogene

EVGN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,767

Bullish sentiment (50-day avg)89%

Price to earnings ratio0.3

Market capitalization6M

Earnings per share-1.75

Dividend yield (TTM)—

Revenue (annual)3.9M

Net income (annual)-7.8M

Social

What share of all stock conversation is about EVGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Jul 17

Evogene Ltd. (EVGN) has a dedicated WhatsApp group for holders to discuss the stock and get the latest information.
The group is open to all investors holding EVGN stock and can be joined by clicking a link on the homepage.
There are multiple posts announcing the WhatsApp group for EVGN holders.

Generated by AI

Sentiment

Of the messages about EVGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	80%	85.71% -14.29	77.63% -2.65
Bearish	0%	20%	14.29% +14.29	22.37% +2.65

Bullish· Jun 11

$EVGN is setting up for a huge move, with a thin float and a key level at $0.62.
The upcoming conference on June 22 is expected to provide company updates and potentially drive the price up until the event.
$EVGN has all the ingredients for a squeeze, including a bottomed-out price, a low float, and upcoming news, making it a stock to keep an eye on.

Bearish· Jun 2

$EVGN is experiencing a significant drop after a vertical pop, with some investors already fading the stock.
The company's recent positive news, including the completion of a Phase 1 clinical study, has not been enough to sustain the stock's momentum, with it hitting a 52-week low.
The stock's high volatility and lack of bounce after even small price increases suggest it may continue to decline, potentially even below $0.50.

Generated by AI

Topics

Of the messages about EVGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	69.23%	69.29%
Technical Analysis	—	0%	0%	8.88%
Analysts	—	0%	0%	6.85%
Controversies	—	0%	30.77%	2.03%
Earnings	—	0%	0%	12.94%
Macro	—	0%	0%	0%

Earnings· Feb 28

Evogene Ltd. ($EVGN) missed earnings estimates by $0.03, but beat revenue expectations.
Evogene Ltd. ($EVGN) reported a quarterly earnings per share (EPS) of $0.24, missing analyst estimates.
Evogene Ltd. ($EVGN) announced its earnings results, which included a miss on EPS expectations by $0.03.

Announcements· Jul 17

A WhatsApp group for Evogene Ltd. ($EVGN) holders has been established to discuss the stock and receive the latest information.
The group is open to all investors holding $EVGN stock and can be joined by clicking the provided link.
Evogene Ltd. ($EVGN) investors are encouraged to join this exclusive group to stay informed and engage with fellow investors.

Technical Analysis· Oct 31

$EVGN is looking for entries above $3.84 to break out.
The stock is in a bullish trend, with a potential 200-day moving average cross-over, and a retest of $2.50 is expected.
A breakout above $2.62 is seen as a key level for $EVGN, with a potential target of $3.00.

Generated by AI

Community

Of the messages about EVGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	81.82%	70.37%	25.69%
Newcomers	100%	18.18%	29.63%	74.31%

Regulars· May 23

Biomica presents positive clinical data update from ongoing phase 1 trial of microbiome-based therapeutic, BMC128, for refractory RCC, NSCLC, and melanoma.
Evogene reports strong Q1 2024 results with revenue jumping to $4.2M from $0.6M last year and net loss reduced by almost half.
Evogene's innovative AI tech-engines, MicroBoost, ChemPass, and GeneRator, address development challenges in life-science based product categories.

Newcomers· Jul 17

Newcomers to investing in EVGN are now aware of a WhatsApp group for EVGN holders, where they can discuss the stock and stay updated on the latest information.
The group aims to provide a platform for EVGN investors to share knowledge, ask questions, and get the latest updates on the stock.
The group's link is available on the homepage, and investors can join by clicking on it or by using the link provided in the message.

Generated by AI

Gainers Evogene (NASDAQ:EVGN) shares increased by 75.0% to $0.72 during Tuesday's after-market session. The company's market cap stands at $4.5 million. AIxCrypto Hldgs (NASDAQ:AIXC) stock moved upwards by

15h agoBenzinga

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today responded to the latest communication from dissident shareholders L.I.A. Pure Capital and Invest-Pro.

1mo agoYahoo Finance

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

1mo agoMorningstar

Evogene (EVGN) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

ISS and Glass Lewis back Evogene board nominees ahead of vote

1mo agoInvesting.com

Evogene Ltd. Q2 2026 Earnings Call Summary

Moby summary of Evogene Ltd.'s Q2 2026 earnings call

1mo agoYahoo Finance

Also Discussed

Investors talking about EVGN also mention

#	Name	Attention
1	AquaBounty Technologies, Inc.AQB	0%0
2	MediWound Ltd.MDWD	0%0
3	ClearBridge Large Cap Growth Select ETFLRGE	0%0
4	NEOS Nasdaq-100 Hedged Equity Income ETFQQQH	0.11%+0.1
5	Optex Systems Holdings, Inc.OPXS	0%0
6	Perdoceo Education CorporationPRDO	0%0
7	First Merchants CorporationFRME	0%0
8	Compugen LtdCGEN	0%new
9	Pacific Biosciences of California, Inc. Common StockPACB	0%0
10	ARK Genomic Revolution ETFARKG	0.25%+0.09

Evogene Ltd.

Healthcare
Biotechnology

Evogene Ltd. is a computational biology and chemistry company focused on life-science product discovery and development. Evogene uses its proprietary AI-driven platforms to design and optimize small molecules, seed traits, ag-chemicals, ag-biologicals, and other products for agriculture, human health, and industrial applications. Its current business is organized around three segments: Agriculture, Human Health, and Industrial Applications. In agriculture, the company works on crop-improvement solutions such as seed traits and biological or chemical inputs that support plant performance. In human health, it develops microbiome-based therapeutics and related discovery programs. In industrial applications, it pursues specialized biological and seed-based solutions for non-food uses. Headquartered in Rehovot, Israel, Evogene serves as a technology platform company that applies computational methods to accelerate product discovery across multiple sectors.

Website

Location

13 Gad Feinstein Street

Rehovot, 7638517

Israel

Social

What share of all stock conversation is about EVGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Jul 17

Evogene Ltd. (EVGN) has a dedicated WhatsApp group for holders to discuss the stock and get the latest information.
The group is open to all investors holding EVGN stock and can be joined by clicking a link on the homepage.
There are multiple posts announcing the WhatsApp group for EVGN holders.

Generated by AI

Sentiment

Of the messages about EVGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	80%	85.71% -14.29	77.63% -2.65
Bearish	0%	20%	14.29% +14.29	22.37% +2.65

Bullish· Jun 11

$EVGN is setting up for a huge move, with a thin float and a key level at $0.62.
The upcoming conference on June 22 is expected to provide company updates and potentially drive the price up until the event.
$EVGN has all the ingredients for a squeeze, including a bottomed-out price, a low float, and upcoming news, making it a stock to keep an eye on.

Bearish· Jun 2

$EVGN is experiencing a significant drop after a vertical pop, with some investors already fading the stock.
The company's recent positive news, including the completion of a Phase 1 clinical study, has not been enough to sustain the stock's momentum, with it hitting a 52-week low.
The stock's high volatility and lack of bounce after even small price increases suggest it may continue to decline, potentially even below $0.50.

Generated by AI

Topics

Of the messages about EVGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	69.23%	69.29%
Technical Analysis	—	0%	0%	8.88%
Analysts	—	0%	0%	6.85%
Controversies	—	0%	30.77%	2.03%
Earnings	—	0%	0%	12.94%
Macro	—	0%	0%	0%

Earnings· Feb 28

Evogene Ltd. ($EVGN) missed earnings estimates by $0.03, but beat revenue expectations.
Evogene Ltd. ($EVGN) reported a quarterly earnings per share (EPS) of $0.24, missing analyst estimates.
Evogene Ltd. ($EVGN) announced its earnings results, which included a miss on EPS expectations by $0.03.

Announcements· Jul 17

A WhatsApp group for Evogene Ltd. ($EVGN) holders has been established to discuss the stock and receive the latest information.
The group is open to all investors holding $EVGN stock and can be joined by clicking the provided link.
Evogene Ltd. ($EVGN) investors are encouraged to join this exclusive group to stay informed and engage with fellow investors.

Technical Analysis· Oct 31

$EVGN is looking for entries above $3.84 to break out.
The stock is in a bullish trend, with a potential 200-day moving average cross-over, and a retest of $2.50 is expected.
A breakout above $2.62 is seen as a key level for $EVGN, with a potential target of $3.00.

Generated by AI

Community

Of the messages about EVGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	81.82%	70.37%	25.69%
Newcomers	100%	18.18%	29.63%	74.31%

Regulars· May 23

Biomica presents positive clinical data update from ongoing phase 1 trial of microbiome-based therapeutic, BMC128, for refractory RCC, NSCLC, and melanoma.
Evogene reports strong Q1 2024 results with revenue jumping to $4.2M from $0.6M last year and net loss reduced by almost half.
Evogene's innovative AI tech-engines, MicroBoost, ChemPass, and GeneRator, address development challenges in life-science based product categories.

Newcomers· Jul 17

Newcomers to investing in EVGN are now aware of a WhatsApp group for EVGN holders, where they can discuss the stock and stay updated on the latest information.
The group aims to provide a platform for EVGN investors to share knowledge, ask questions, and get the latest updates on the stock.
The group's link is available on the homepage, and investors can join by clicking on it or by using the link provided in the message.

Generated by AI

Evogene

Social

Jul 17

Bullish· Jun 11

Bearish· Jun 2

Earnings· Feb 28

Announcements· Jul 17

Technical Analysis· Oct 31

Regulars· May 23

Newcomers· Jul 17

12 Health Care Stocks Moving In Tuesday's After-Market Session - Evogene (NASDAQ:EVGN), AIxCrypto Hldgs (

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

Evogene (EVGN) Q2 2026 Earnings Call Transcript

ISS and Glass Lewis back Evogene board nominees ahead of vote

Evogene Ltd. Q2 2026 Earnings Call Summary

Also Discussed

Evogene Ltd.

Company Information

Location

12 Health Care Stocks Moving In Tuesday's After-Market Session - Evogene (NASDAQ:EVGN), AIxCrypto Hldgs (

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

Evogene (EVGN) Q2 2026 Earnings Call Transcript

ISS and Glass Lewis back Evogene board nominees ahead of vote

Evogene Ltd. Q2 2026 Earnings Call Summary

Also Discussed

Social

Jul 17

Bullish· Jun 11

Bearish· Jun 2

Earnings· Feb 28

Announcements· Jul 17

Technical Analysis· Oct 31

Regulars· May 23

Newcomers· Jul 17